Background: Skeletal muscle atrophy is characterized by muscle wasting with partial or complete functional loss. Skeletal muscle atrophy severely affects the quality of life and currently, there is no available therapy except for spinal muscular atrophy.
Objective: Drug repositioning is a promising strategy that reduces cost and time due to prior availability of safety and toxicity details.